Tacrolimus based immunosuppression

Journal of Nephrology

Volumn 17, Issue SUPPL. 8, 2004, Pages

  First, M Roy ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Cardiovascular risk; Post transplant diabetes mellitus; Rejection; Renal function; Renal transplantation; Tacrolimus

Indexed keywords

CYCLOSPORIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MICROEMULSION; REVIEW; DRUG EFFECT; KIDNEY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; RISK FACTOR;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TACROLIMUS;

EID: 16644378398     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Meier-Kriesche H-U, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strateies? Am J Transplant 2004; 4: 1289-95.
2. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-90.
3. UNOS Market Share Report, March, 2004.
4. Jindal RM, Hariharan S. Chronic rejection in kidney transplants. An in-depth review. Nephron 1999; 83: 13-24.
5. Humar A, Hassoun A, Kandaswamy R, Payne WD, Sutherland DE, Matas AJ. Immunologic factors: the major risk for decreased long-term renal allograft survival. Transplantation 1999; 68: 1842-6.
6. Meier-Kriesche H-U, Ojo AO, Hanson JA, Cibrik DM, Punch JD, Leichtman AB, Kaplan B. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098-100.
7. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988-96. N Engl J Med 2000; 342: 605-12.
8. Mayer AD, Dmitrewski J, Suqifflet J-P, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436-43.
9. Mayer AD for the European Tacrolimus Multicentre Renal Study Group. Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34: 1491-2.
10. Margreiter R, for the European Tacrolimus vs Cyclosporine Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-6.
11. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS, for the FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-83.
12. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-terin kidney transplant survival. Kidney Int 2002; 62: 311-8.
13. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-82.
14. Gill JS, Tonelli M, Mix CH, Johnson N, Pereira BJG. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 2004; 65: 692-9.
15. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980-4.
16. Jurewicz WA. Tacrolimus versus cyclosporine immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 (suppl 1): S7-11.
17. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002; 61: 686-96.
18. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732-6.
19. Cherikh WS, Kauffman HM, Maghirang J, Bleyer AJ, Johnson CP. A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. Transplantation 2003; 76: 463-70.
20. Bresnahan BA, Cherikh WS, Cheng Y, Siddiqi NA, Hariharan S. Short-term benefit of tacrolimus vs cyclosporine therapy after renal transplantation: an analysis of UNOS/OPTN database. (Abstract 1213). Am J Transplant 2003; 3 (suppl 5): S462.
21. Bunnapradist S, Daswani A, Takemoto SK. Graft survival following living-donor renal transplantation: A comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation 2003; 76: 10-5.
22. Data retrieved from wwW.ctstransplant.org (September 2003).
23. Krämer BK, Zülke C, Kammerl MC, Schmidt C, Hengstenberg C, Fischereder M, Marienhagen J. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982-87.
24. Wissing KM, Abramowicz D, Broeders N, Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70: 464-72.
25. Margreiter R, Pohanka E, Sparacino V, Sperschneider H, Kunzendorf U. Large European study of the switch to tacrolimus for cyclosporine-related side effects. (Abstract 1060). Am J Transplant 2002; 2 (suppl 3): S405.
26. Friemann S, Stopp K, Christ B, Weiner R, Padberg W, Ernst W. Conversion to tacrolimus in hyperlipidemic patients. Transplant Proc 1999; 31 (suppl 7A): S41-3.
27. McCune TR, Thacker LR, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation 1998; 65: 87-92.
28. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732-7.
29. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440-6.
30. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-85.
31. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583-95.
32. First MR. New-onset diabetes after transplantation. Transplantation 2004; 77: 1128-9.
33. Alisan N, Johnson C, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Salm K, Tolzman D, Fitzsimmons WE. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophe-nolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72: 245-50.
34. Romagnoli J, Citterio F, Violi P, Nanni G, Castagneto M. Posttransplant diabetes mellitus after kidney transplantation with different immunosuppressive agents. Transplant Proc 2004; 36: 690-1.
35. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, Grenda R, Janda J, Hughes D, Ehrich JH, Klare B, Zacchello G, Bjorn Brekke I, McGraw M, Perner F, Ghio L, Balzar E, Friman S, Gusmano R, Stolpe J. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Paediatr Nephrol 2002; 17: 141-9.
36. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: Incidence, risk factors, and management. Transplantation 2002; 73: 379-86.
37. van Duijnhoren EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13: 213-20.
38. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221-7.
39. Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 2001; 14: 370-83.
40. Boots JM, Christiaans MH, van Duijnhoven EM, van Suylen RJ, van Hooff JP. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-9.
41. Pascual J, Rigotti P, Vialtel P, Sanchez-Fructuoso A, Escuin F. Immunosuppression without steroids: a daclizumab, tacrolimus and MMF prevents loss of bone mass following renal transplantation. Proceedings of the 11th Congress of the European Society for Organ Transplantation 2003; 104 (Abstract 369).
42. Bakran A, Short C, Torregrosa V, Nicholson M, Cambi V. Reducing the immunosuppression load: A head to head comparison of tacrolimus monotherapy with cyclosporine monotherapy after kidney transplantation. Proceedings of the 11th Congress of the European Society for Organ Transplantation 2003; 101 (Abstract 354).